Volker W. Stieber, MD
Department of Radiation Oncology
Wake Forest University
Physician CME: 1.0
Nursing CE: 1.0 (0.1 CEU) Medium
CREDIT FOR THIS ACTIVITY IS AVAILABLE FOR PHYSICIANS AND NURSES ONLY.
This online capture of a grand rounds presentation was originally presented on September 24, 2007, at Forsyth Medical Center in Winston-Salem, NC. If you received credit from the live grand rounds presentation, you are not eligible to apply for credit through this online version.
While primary gliomas represent a small percentage of cancers, they continue to pose a large clinical challenge. Surgical resection, while beneficial, is never curative and conventional treatment, such as radiation therapy, only delays tumor regrowth. Therefore the prognosis remains bleak for the majority of primary malignant glioma patients. However, newer treatment combinations and recent biomarker discoveries are yielding improved time-to-progression and survival rates. This Grand Rounds program will present available data to critically evaluate treatment options for patients with varying types of malignant gliomas. Ongoing and recently completed trials in radiation, surgery, radiosurgery, chemotherapy, and targeted agents will be discussed. This Grand Rounds program, developed by experts in radiation oncology, neuro-oncology, neurosurgery, molecular biology, pathology, and neuro-oncology nursing has been designed for clinicians who interact with oncology patients.
. Target Audience
This program has been designed for physicians and advance practice nurses who interact with oncology patients.
Upon completion of this educational activity, the participant should be able to:
Identify the histologic subtypes of primary gliomas and the prognosis typical of each.
Discuss the importance of clinical and molecular biomarkers in identifying prognostic variables.
Review the clinical trial evidence that led to defining combination chemoradiotherapy as the new standard of care for some malignant gliomas.
Discuss the rationale of salvage treatment strategies for patients with recurrent glioma.
In meeting the requirements of full disclosure and in compliance with the Accreditation Council for Continuing Medical Education Essentials, Standards for Commercial Support and Guidelines, the Education Steering Committee has provided the following information regarding potential conflicts of interest. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Stieber discloses that he serves on advisory committees for Cytyc Corporation and Monteris Medical.
This educational activity may contain discussion of investigational uses of pharmaceutical agents or surgical devices. Some of these agents/devices may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media.
AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU).
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. There is no fee to participate and receive credit.
Commercial Support Statements
Supported through an educational grant from Schering-Plough.
Please turn off all pop-up blockers and click on the "Start Program" icon. If you are not previously logged in to the site, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Start Program" icon.
The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. This program, post-test, and evaluation will take approximately 60 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE certificate.
None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed are those of the presenter and do not necessarily reflect the opinions or recommendations of his affiliated institution, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenter should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.